Thompson Siegel & Walmsley LLC Trims Stock Holdings in HCA Healthcare, Inc. (NYSE:HCA)

Thompson Siegel & Walmsley LLC cut its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 12.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,228 shares of the company’s stock after selling 2,172 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in HCA Healthcare were worth $4,892,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in HCA. Thoroughbred Financial Services LLC lifted its stake in shares of HCA Healthcare by 28.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 19,087 shares of the company’s stock valued at $6,132,000 after purchasing an additional 4,278 shares in the last quarter. Dai ichi Life Insurance Company Ltd increased its position in shares of HCA Healthcare by 62.6% in the second quarter. Dai ichi Life Insurance Company Ltd now owns 26,970 shares of the company’s stock worth $8,665,000 after acquiring an additional 10,381 shares in the last quarter. Valley Wealth Managers Inc. boosted its position in HCA Healthcare by 3.4% during the 2nd quarter. Valley Wealth Managers Inc. now owns 1,209 shares of the company’s stock worth $388,000 after purchasing an additional 40 shares during the period. Meeder Advisory Services Inc. lifted its stake in shares of HCA Healthcare by 38.4% during the second quarter. Meeder Advisory Services Inc. now owns 5,270 shares of the company’s stock worth $1,693,000 after purchasing an additional 1,462 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of HCA Healthcare by 3.3% in the second quarter. DekaBank Deutsche Girozentrale now owns 99,690 shares of the company’s stock valued at $34,074,000 after buying an additional 3,184 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Stock Up 0.8 %

Shares of HCA opened at $394.68 on Monday. HCA Healthcare, Inc. has a 12 month low of $215.96 and a 12 month high of $403.05. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 27.11. The company has a 50-day moving average price of $362.19 and a two-hundred day moving average price of $338.12. The stock has a market cap of $101.86 billion, a price-to-earnings ratio of 19.67, a P/E/G ratio of 1.46 and a beta of 1.67.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.97 by $0.53. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. The firm had revenue of $17.49 billion for the quarter, compared to the consensus estimate of $17.05 billion. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.29 EPS. Equities analysts predict that HCA Healthcare, Inc. will post 22.46 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 16th will be given a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Monday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is 13.16%.

Insider Buying and Selling

In other news, EVP Michael S. Cuffe sold 8,358 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now owns 29,678 shares in the company, valued at approximately $11,438,494.76. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, SVP Kathleen M. Whalen sold 2,987 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $363.51, for a total transaction of $1,085,804.37. Following the completion of the sale, the senior vice president now owns 9,454 shares of the company’s stock, valued at approximately $3,436,623.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the transaction, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,202 shares of company stock worth $6,407,273. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Oppenheimer lifted their price objective on shares of HCA Healthcare from $345.00 to $390.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Leerink Partners upped their price objective on shares of HCA Healthcare from $367.00 to $396.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $392.00 price objective on shares of HCA Healthcare in a report on Monday, August 19th. Morgan Stanley assumed coverage on HCA Healthcare in a report on Tuesday, September 3rd. They set an “equal weight” rating and a $427.00 target price on the stock. Finally, Barclays upped their price target on HCA Healthcare from $376.00 to $396.00 and gave the company an “overweight” rating in a report on Wednesday, July 24th. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, HCA Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $359.89.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.